Maintenance on Wegovy is a phase of treatment, not the end of it. What the maintenance dose is, what STEP 4 found about staying on versus stopping, and the signals that move before the scale does.
2.4 mgThe licensed Wegovy maintenance dose, reached around week 17
−7.9%Further weight change continuing in STEP 4 weeks 20–68
+6.9%Weight change switching to placebo over the same period
14.8 ptsThe gap between those two decisions
Key takeaways
Wegovy maintenance means staying on 2.4 mg, the dose used in the STEP trials and in the 17,604-person SELECT cardiovascular outcomes trial — not tapering off after reaching a goal.
STEP 4 is the trial that answers the maintenance question directly: continuing gave a further 7.9% loss over weeks 20 to 68, while switching to placebo gave a 6.9% gain.
A plateau is not the same as maintenance. One is your weight settling at a dose that is still working; the other is a deliberate plan.
The signals worth watching in maintenance are food noise, protein intake and dose timing — all of which move before the scale does.
Lower maintenance doses exist as a clinical conversation, not as something to trial between appointments.
Maintenance is a phase of treatment, not the end of it. Wegovy's approved
schedule climbs 0.25 to 0.5 to 1 to 1.7 mg, reaching 2.4 mg at around week seventeen, and 2.4 mg
is the maintenance dose. Not a peak you come down from.
That trips people up because most medication courses have an end. Antibiotics finish.
Wegovy is licensed as long-term treatment for a chronic condition, and the trials that
established it kept people on it. When weight stabilises at 2.4 mg, the drug has not stopped
working — it is doing the second half of its job.
The titration schedule tool maps the whole
escalation with dates if you want to see where you are in it.
The evidence for staying on
STEP 4 was designed to answer exactly this question, and its answer is unusually
clean. Participants ran in on semaglutide for 20 weeks, then were randomised either to
continue at 2.4 mg or to switch to placebo.
STEP 4, mean body weight change over weeks 20 to 68. Source: Rubino et al., JAMA, 2021.
Group
Weight change, weeks 20–68
Continued semaglutide 2.4 mg
−7.9%
Switched to placebo
+6.9%
Estimated treatment difference
−14.8 percentage points
Same people, same starting point, one decision, a 14.8-point spread. The longer-horizon
version comes from the STEP 1 extension, where people who stopped regained about two-thirds of
their lost weight over the following year.
There is a second argument that has nothing to do with weight. SELECT randomised 17,604
adults with cardiovascular disease and obesity to semaglutide 2.4 mg or placebo and found major
adverse cardiovascular events in 6.5% versus 8.0% over a mean of 39.8 months. If that benefit is
part of why you are on it, it is a benefit that requires being on it.
Plateau versus maintenance
A plateau is weight loss stopping while you are still climbing or still expect to
lose. Maintenance is weight holding on purpose. They feel identical and mean different
things.
The distinction matters because the responses are opposite. A plateau at week ten on 1 mg
usually means the dose has not finished escalating, or that intake has drifted, or that both
are true. Stable weight at month nine on 2.4 mg after a substantial loss is closer to the
treatment doing what it was prescribed to do.
Three questions separate them: is the dose still climbing, has food noise changed, and has
protein or portion size drifted. Weight alone cannot tell you, which is why weight alone is a
poor maintenance metric. Waist measurements, strength, blood pressure, glucose control and the
volume of food noise all carry information the scale does not.
Can you maintain on a lower dose?
Some people do, and it is a legitimate conversation — but Wegovy's licensed
maintenance dose is 2.4 mg, and the maintenance evidence was generated at 2.4 mg.
Reasons people ask are usually cost, side effects, or supply. Each has a different best
answer, and only one of them is "take less". Side effects at maintenance are worth reporting
rather than solving privately, because they are often manageable without changing dose. Cost has
named alternatives that do not involve rationing. Supply gaps are events to plan a restart
around.
What is worth agreeing in advance either way is the threshold: how much regain, or how much
returning food noise, triggers a review. A number decided in advance beats a judgement call made
while it is happening.
Stretching the interval between injections to make a pen last is the most
commonly improvised version of this, and it is the one to raise before doing rather than after.
It changes drug levels and re-introduces the side effects that come with re-escalation.
What changes when the losing stops
Maintenance has its own failure modes, and they are not the ones from the losing
phase.
Protein slips. Appetite is still suppressed but the urgency is gone, and protein is
the first thing to fall. It is also the main defence against losing lean tissue. A target
number helps more than intention — the protein
calculator gives you one.
Weighing stops. Understandable, and it removes the signal that would have caught
drift at three pounds instead of fifteen.
Food noise creeps back. Usually gradual, usually before the scale moves. The most
useful early indicator there is.
Resistance training gets dropped. It mattered during loss and it matters more during
maintenance, when the goal is keeping what you rebuilt.
Appointments get further apart. Which is fine, as long as somebody is still watching
the numbers.
What to track through a transition
The useful signals move before the scale does, and none of them are things anyone
remembers accurately three weeks later. If you are changing anything about your
treatment, these four are worth writing down as they happen:
Food noise. Intrusive food thoughts, grazing urges, whether old portions have
started looking normal again. This is usually the first thing to move.
Hunger pattern. Not just how often, but whether meals still finish the feeling.
Weight trend, weekly. A seven-day average, not a daily number. Daily weights during
a transition mostly measure hydration and generate anxiety.
Dose history. Exact dates of every change, missed dose, dose stretch, side effect
and supply gap. This is the part clinicians most often ask about and patients most often
cannot answer.
The point is not to become a data project. It is that "hunger came back around week three
and I was up four pounds by week six" is a conversation that produces a plan, while "I think
it's been getting worse" is not.
Common questions
What is the maintenance dose of Wegovy?
2.4 mg once weekly, reached at around week seventeen on the standard escalation. It is the dose used in the STEP weight-management trials and in the SELECT cardiovascular outcomes trial.
How long do you stay on Wegovy?
It is licensed as long-term treatment for a chronic condition rather than a fixed course. The trial evidence is specifically that continuing maintains the result and stopping largely reverses it. How long applies to you is a clinical decision, but the default in the evidence is ongoing.
Can you maintain weight loss on a lower Wegovy dose?
Some people do, and it is a reasonable question to raise, but 2.4 mg is the licensed maintenance dose and where the maintenance evidence comes from. Lower-dose maintenance is a prescriber decision, not something to trial between appointments.
Is a Wegovy plateau the same as maintenance?
No. A plateau is weight loss stalling while you still expect to lose, often because the dose is still escalating or intake has drifted. Maintenance is weight holding by design at the maintenance dose. The tell is whether food noise, protein and portion size have changed.
What happens if I stop Wegovy after reaching my goal?
In STEP 4, people switched to placebo after a 20-week run-in gained 6.9% over the following 48 weeks while those continuing lost a further 7.9%. In the STEP 1 extension, about two-thirds of lost weight returned within a year of stopping.
Sources
Every figure on this page traces to one of these. Regulatory documents and
peer-reviewed primary research only — see our editorial policy
for what we accept as a source.
Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 2021. View source
Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022. View source
Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 2023. View source
WEGOVY (semaglutide) injection, US prescribing information. FDA, 2025. View source
GLP-1 Agonists: What They Are, How They Work & Side Effects. Cleveland Clinic. View source
Maintenance needs better signals than the scale
GLPme tracks food noise, protein and weight trend together, so drift shows up while it is still small enough to be a conversation rather than a restart. Core tracking is free.